Scholarlink

<p>The <i>ASXL1</i> gene is one of the most frequently mutated genes in acute myeloid leukemia (AML). It is associated with signs of aggressiveness and adverse clinical outcomes. The aim of the current study was to analyze the genetic profile of <i>ASXL1</i> gene mutations and its impact on the overall survival in AML patients from Pakistan.</p><p>Thirty-eight well characterized AML patients were enrolled, and DNA sequencing of the <i>ASXL1</i> was performed using the Illumina NextSeq500 next generation sequencing (NGS) system. Standard pipeline of bioinformatics tools was used to determine the mutational profile. The mutational profile of the enrolled AML patients was compared with that of 1000 Genomes project, and TCGA AML datasets.</p><p>The analysis revealed 43 genetic variants in <i>ASXL1</i> across the 38 AML patients (1.13 variant/patient). Eight rare variants were observed in exons 12, 13 of the <i>ASXL1</i> gene. Notably, a recurrent rare nonsynonymous deleterious variant p.G1336S in exon 13 (NM_015338 transcript) was found in two patients (5.26%). The overall survival of the <i>ASXL1+</i> (but <i>TP53</i>, <i>FLT3</i>, <i>NPM1</i>, <i>EZH2</i>, and <i>WT1</i> negative) AML was shorter compared with the <i>ASXL1-</i> (<i>p</i> &lt; 0.05). Further, the overall survival of current study <i>ASXL1 +</i> AML was found comparable with that of the TCGA AML.</p><p>In conclusion, the non-silent mutations in <i>ASXL1</i> were associated with lower survival in AML. Further studies with larger cohort are suggested for subsequent clinical implementation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetic profile of ASXL1 gene in risk assessment in acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月12日

查看全文
  • Salem Ahmed Bamusa,
  • Wardah Qureshi,
  • Atia Gohar,
  • Muhammad Irfan,
  • Ishtiaq Ahmad Khan,
  • Muhammad Shakeel

摘要

The ASXL1 gene is one of the most frequently mutated genes in acute myeloid leukemia (AML). It is associated with signs of aggressiveness and adverse clinical outcomes. The aim of the current study was to analyze the genetic profile of ASXL1 gene mutations and its impact on the overall survival in AML patients from Pakistan.

Thirty-eight well characterized AML patients were enrolled, and DNA sequencing of the ASXL1 was performed using the Illumina NextSeq500 next generation sequencing (NGS) system. Standard pipeline of bioinformatics tools was used to determine the mutational profile. The mutational profile of the enrolled AML patients was compared with that of 1000 Genomes project, and TCGA AML datasets.

The analysis revealed 43 genetic variants in ASXL1 across the 38 AML patients (1.13 variant/patient). Eight rare variants were observed in exons 12, 13 of the ASXL1 gene. Notably, a recurrent rare nonsynonymous deleterious variant p.G1336S in exon 13 (NM_015338 transcript) was found in two patients (5.26%). The overall survival of the ASXL1+ (but TP53, FLT3, NPM1, EZH2, and WT1 negative) AML was shorter compared with the ASXL1- (p < 0.05). Further, the overall survival of current study ASXL1 + AML was found comparable with that of the TCGA AML.

In conclusion, the non-silent mutations in ASXL1 were associated with lower survival in AML. Further studies with larger cohort are suggested for subsequent clinical implementation.